Immune checkpoint inhibitors in melanoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer 40(12), 1825–1836 (2004).
  Medline CASGoogle Scholar
• 2 Bennet WH. Some peculiarities in the behaviour of certain malignant and innocent growths. Lancet 1, 3–7 (1899).
  Google Scholar
• 3 Nathanson. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst. Monogr. 44, 67–76 (1976).
  Medline CASGoogle Scholar
• 4 Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 19(5), 275–282 (2009).
  MedlineGoogle Scholar
• 5 Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM. Three consecutive Phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer 59(3 Suppl.), 638–646 (1987).
  Medline CASGoogle Scholar
• 6 Ascierto PA, Gogas HJ, Grob JJ et al. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit. Rev. Oncol. Hematol. 85(2), 149–161 (2013).
  MedlineGoogle Scholar
• 7 Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 102(7), 493–501 (2010).
  Medline CASGoogle Scholar
• 8 Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6(Suppl. 1), S11–S14 (2000).
  MedlineGoogle Scholar
• 9 Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316(15), 889–897 (1987).
  Medline CASGoogle Scholar
• 10 Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159–1166 (1994).
  Medline CASGoogle Scholar
• 11 Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550–4557 (2011).
  Medline CASGoogle Scholar
• 12 Kershaw MH, Westwood JA, Slaney CY, Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin. Transl. Immunol. 3(5), e16 (2014).
  MedlineGoogle Scholar
• 13 Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535–546 (2009).
  Medline CASGoogle Scholar
• 14 Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119–2127 (2011).
  Medline CASGoogle Scholar
• 15 Vantomme V, Dantinne C, Amrani N et al. Immunologic analysis of a Phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J. Immunother. 27(2), 124–135 (2004).
  Medline CASGoogle Scholar
• 16 Kruit W, Suciu S, Dreno B et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label Phase II study of the EORTC Melanoma Group (16032–18031). Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
  Google Scholar
• 17 Louahed J, Gruselle O, Gaulis S et al. Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032–18031). Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May–3 June 2008.
  Google Scholar
• 18 GSK - The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial. www.gsk.com
  Google Scholar
• 19 Morton DL, Hoon DS, Nizze JA et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann. NY Acad. Sci. 690, 120–134 (1993).
  Medline CASGoogle Scholar
• 20 Morton Dl MN, Thompson JF, Kelley MC, Faries M, Wagner J. An international randomized, Phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J. Clin. Oncol. 25(18S Suppl.), 8508 (2007).
  Google Scholar
• 21 Livingston PO, Wong G, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12(5), 1036–1044 (1994).
  Medline CASGoogle Scholar
• 22 Eggermont AM, Suciu S, Rutkowski P et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC18961 randomized Phase III trial. J. Clin. Oncol. 31(30), 3831–3837 (2013).
  Medline CASGoogle Scholar
• 23 Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370–2380 (2001).
  Medline CASGoogle Scholar
• 24 Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol. Rev. 229(1), 88–100 (2009).
  Medline CASGoogle Scholar
• 25 Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7(2), 95–106 (2007).
  Medline CASGoogle Scholar
• 26 Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother. 58(5), 823–830 (2009).
  Medline CASGoogle Scholar
• 27 Hodi FS, O’day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).•• This seminal paper reported on a Phase III ipilimumab trial that was the first to show a survival benefit in metastatic melanoma.
  Medline CASGoogle Scholar
• 28 Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
  Medline CASGoogle Scholar
• 29 Maio M, Bondarenko I, Robert C et al. Survival analysis with 5 years of follow-up in a Phase III study of ipilimumab and dacarbazine in metastatic melanoma. Presented at: ESMO European Cancer Congress 2013. Amsterdam, Netherlands, 27 September–1 October 2013 (Abstract 3704).
  Google Scholar
• 30 Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Presented at: ESMO European Cancer Congress 2013. Amsterdam, Netherlands, 27 September–1 October 2013 (Abstract LBA 24).• This review demonstrates the durable nature of responses to ipilimumab therapy with the 3 year survival rate of around 20% maintained out to 10 years.
  Google Scholar
• 31 Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19(16), 3635–3648 (2001).
  Medline CASGoogle Scholar
• 32 Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27(7), 1075–1081 (2009).
  Medline CASGoogle Scholar
• 33 Kirkwood JM, Lorigan P, Hersey P et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 16(3), 1042–1048 (2010).
  Medline CASGoogle Scholar
• 34 Ribas A, Kefford R, Marshall MA et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31(5), 616–622 (2013).
  Medline CASGoogle Scholar
• 35 Ribas A, Hauschild A, Kefford R, Wilson KS et al. J. Clin. Oncol. 31(22), 2836–2837 (2013).
  MedlineGoogle Scholar
• 36 O’day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm Phase II study. Ann. Oncol. 21(8), 1712–1717 (2010).
  MedlineGoogle Scholar
• 37 Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase II, dose-ranging study. Lancet Oncol. 11(2), 155–164 (2010).
  Medline CASGoogle Scholar
• 38 Wolchok JD, Hoos A, O’day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412–7420 (2009).
  Medline CASGoogle Scholar
• 39 Ascierto PA, Simeone E, Sileni VC et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J. Transl. Med. 12, 116 (2014).
  MedlineGoogle Scholar
• 40 Berrocal A, Arance A, Lopez Martin JA et al. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res. 24(6), 577–583 (2014).
  Medline CASGoogle Scholar
• 41 Chiarion Sileni V, Pigozzo J, Ascierto PA et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J. Exp. Clin. Cancer Res. 33, 30 (2014).
  MedlineGoogle Scholar
• 42 Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371(23), 2189–2199 (2014).
  Medline CASGoogle Scholar
• 43 Lutzky J, Wolchok J, Hamid O et al. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three Phase II clinical trials. 2009 American Society of Clinical Oncology (ASCO) meeting. J. Clin. Oncol. 27(15s), Abstract 9034 (2009).
  MedlineGoogle Scholar
• 44 Adaniel C, Rendleman J, Polsky D et al. Germline genetic determinants of immunotherapy response in metastatic melanoma. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 30 May–3 June 2014 (Abstract 3004).
  Google Scholar
• 45 Di Giacomo AM, Calabro L, Danielli R et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol. Immunother. 62(6), 1021–1028 (2013).
  Medline CASGoogle Scholar
• 46 Yuan J, Adamow M, Ginsberg BA et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl Acad. Sci. USA 108(40), 16723–16728 (2011).
  Medline CASGoogle Scholar
• 47 Yuan J, Zhou J, Dong Z et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol. Res. 2(2), 127–132 (2014).
  Medline CASGoogle Scholar
• 48 Meyer C, Cagnon L, Costa-Nunes CM et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63(3), 247–257 (2014).
  Medline CASGoogle Scholar
• 49 Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691–2697 (2012).
  Medline CASGoogle Scholar
• 50 Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24(15), 2283–2289 (2006).
  Medline CASGoogle Scholar
• 51 Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother. Radiopharm. 24(3), 321–325 (2009).
  Medline CASGoogle Scholar
• 52 Chmiel KD, Suan D, Liddle C et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J. Clin. Oncol. 29(9), e237–e240 (2011).
  Medline CASGoogle Scholar
• 53 Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368(14), 1365–1366 (2013).
  Medline CASGoogle Scholar
• 54 Puzanov I, Callahan MK, Linette GP et al. Phase I study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). ASCO Annual Meeting. Chicago, IL, USA, 30 May–3 June 2014 (Abstract 2511).
  Google Scholar
• 55 Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J. Transl. Med. 10, 107 (2012).
  Medline CASGoogle Scholar
• 56 Ackerman A, Klein O, Mcdermott DF et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120(11), 1695–1701 (2014).
  Medline CASGoogle Scholar
• 57 Schreuer MS, Chevolet IL, Jansen YJ et al. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Res. 25(1), 68–74 (2014).
  Google Scholar
• 58 Wilmott JS, Long GV, Howle JR et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18(5), 1386–1394 (2012).
  Medline CASGoogle Scholar
• 59 Frederick DT, Piris A, Cogdill AP et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19(5), 1225–1231 (2013).
  Medline CASGoogle Scholar
• 60 D’Angelo S, Dickson M, Kelly N, Yaqubie A, Chapman P. Switching therapy pre-emptively from vemurafenib (VEM) to ipilimumab (IPI) in patients (pts) with BRAF-mutated melanoma (MEL). Society for Melanoma Research 10th International Congress 2013. Philadelphia, PA, USA, 17–20 November 2013.
  Google Scholar
• 61 Chan MM, Haydu LE, Menzies AM et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer 120(20), 3142–3153 (2014).
  Medline CASGoogle Scholar
• 62 Carlino MS, Gowrishankar K, Saunders CA et al. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol. Cancer Ther. 12(7), 1332–1342 (2013).
  Medline CASGoogle Scholar
• 63 Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8(6), 467–477 (2008).
  Medline CASGoogle Scholar
• 64 Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).• This paper reports on the impressive response rates seen with the PD-1 antibody pembrolizumab in a large Phase I trial.
  Medline CASGoogle Scholar
• 65 Ribas A, Hodi FS, Kefford R et al. Efficacy and safety of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients (pts) with melanoma (MEL). Presented at: ASCO Annual Meeting. Chicago, IL, USA, 30 May–3 June 2014 (Abstract LBA9000).
  Google Scholar
• 66 Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase I trial. Lancet 384(9948), 1109–1117 (2014).
  Medline CASGoogle Scholar
• 67 Ribas A, Puzanov I, Dummer R et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory (IPI-R) melanoma (MEL). (Late breaking abstract) Presented at: Society for Melanoma Research 2014 International Congress. Zurich, Switzerland, 13–16 November 2014.
  Google Scholar
• 68 Topalian SL, Sznol M, Mcdermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32(10), 1020–1030 (2014).
  Medline CASGoogle Scholar
• 69 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  Medline CASGoogle Scholar
• 70 Weber JS, Minor DR, D’Angelo S et al. A Phase III randomized, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA4 therapy. Ann. Oncol. 25(5), 1–41 (2014).
  Google Scholar
• 71 Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl J. Med. 372(4), 320–330 (2014).•• This paper reports on a Phase III trial (in BRAF wild-type patients) clearly demonstrating the superiority of the PD-1 inhibitor nivolumab over chemotherapy in the first-line setting.
  MedlineGoogle Scholar
• 72 Atkins MB, Kudchadkar RR, Sznol M et al. Phase II, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma (abstract 9001). Presented at: ASCO Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 73 Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
  Medline CASGoogle Scholar
• 74 Hamid O, Sosman JA, Lawrence DP et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (abstract #9010). Presented at: ASCO Annual Meeting 2013. Chicago, USA, 31 May–4 June 2013.
  Google Scholar
• 75 Chan MM, Kefford RF, Carlino M, Clements A, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J. Immunother. 38(1), 37–39 (2015).
  Medline CASGoogle Scholar
• 76 Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122–133 (2013).• This paper reports the impressive responses seen in a Phase I trial of the combination of nivolumab and ipilimumab, and highlights the increased toxicity seen with the combination.
  Medline CASGoogle Scholar
• 77 Sznol M, Kluger HM, Callahan MK et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) (abstract LBA9003). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 78 Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20(19), 5064–5074 (2014).
  Medline CASGoogle Scholar
• 79 Kefford R, Ribas A, Hamid O et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 (abstract 3005). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 80 Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568–571 (2014).
  Medline CASGoogle Scholar
• 81 Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC18071 Phase III trial (abstract LBA9008). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 82 Hodi FS, Lee S, Mcdermott DF et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312(17), 1744–1753 (2014).
  Medline CASGoogle Scholar
• 83 Puzanov I, Milhem MM, Andtbacka RHI et al. Primary analysis of a Phase Ib multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma (abstract 9029). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 84 Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925–931 (2012).
  Medline CASGoogle Scholar
• 85 Grimaldi AM, Simeone E, Giannarelli D et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 3, e28780 (2014).
  MedlineGoogle Scholar
• 86 Barker CA, Postow MA, Khan SA et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol. Res. 1(2), 92–98 (2013).
  Medline CASGoogle Scholar
• 87 Sznol M, Hodi FS, Margolin K et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology 2008. Chicago, IL, USA, 30 May–3 June 2008 (Abstract 3007).
  Google Scholar
• 88 Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J. Exp. Med. 211(4), 715–725 (2014).
  Medline CASGoogle Scholar
• 89 Derre L, Rivals JP, Jandus C et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 120(1), 157–167 (2010).
  Medline CASGoogle Scholar
• 90 Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13(4), 227–242 (2013).
  MedlineGoogle Scholar